Aberrant vascular architecture in tumors and its importance in drug-based therapies.
暂无分享,去创建一个
[1] H. Dvorak. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.
[2] Paul S. Meltzer,et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[3] R K Jain,et al. Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.
[4] H. Dvorak,et al. The vesiculo‐vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation , 1996, Journal of leukocyte biology.
[5] J. Isner,et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.
[6] Rakesh K Jain,et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.
[7] E. Ruoslahti,et al. Fibronectin and its integrin receptors in cancer. , 1999, Advances in cancer research.
[8] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.
[9] G. Palade,et al. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. , 1995, Journal of cell science.
[10] R. Hesketh,et al. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue , 2001, British Journal of Cancer.
[11] W. Westlin. Integrins as targets of angiogenesis inhibition. , 2001, Cancer journal.
[12] R K Jain,et al. Determinants of tumor blood flow: a review. , 1988, Cancer research.
[13] Rakesh K. Jain,et al. Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.
[14] R K Jain,et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[15] R K Jain,et al. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.
[16] Y. Sasaki,et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[17] Grietje Molema,et al. Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature , 1997, Science.
[18] S. Ran,et al. Tumor infarction by targeting tissue factor to tumor vasculature. , 2000, Cancer journal.
[19] N. Fausto. Vasculogenic mimicry in tumors. Fact or artifact? , 2000, The American journal of pathology.
[20] A. Foss,et al. Endothelial Cells of Tumor Vessels: Abnormal but not Absent , 2004, Cancer and Metastasis Reviews.
[21] Chemoprevention of intestinal polyposis in the APCΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor , 2000 .
[22] R Folberg,et al. Vasculogenic mimicry and tumor angiogenesis. , 2000, The American journal of pathology.
[23] R. Jain. The next frontier of molecular medicine: Delivery of therapeutics , 1998, Nature Medicine.
[24] C. Betsholtz,et al. Analysis of Mural Cell Recruitment to Tumor Vessels , 2002, Circulation.
[25] P. Friedl,et al. The biology of cell locomotion within three-dimensional extracellular matrix , 2000, Cellular and Molecular Life Sciences CMLS.
[26] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[27] Michael D Feldman,et al. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. , 2003, The American journal of pathology.
[28] D. Ingber. Extracellular matrix as a solid-state regulator in angiogenesis: identification of new targets for anti-cancer therapy. , 1992, Seminars in cancer biology.
[29] A. Levine,et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. , 2000, The Journal of urology.
[30] Philippe Shubik,et al. Vascularization of tumors: A review , 2004, Journal of Cancer Research and Clinical Oncology.
[31] D. Chaplin,et al. The development of combretastatin A4 phosphate as a vascular targeting agent. , 2002, International journal of radiation oncology, biology, physics.
[32] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[33] R. Xavier,et al. Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.
[34] R K Jain,et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] R. Jain,et al. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. , 1996, Microvascular research.
[36] P. Shubik,et al. The growth of the blood supply to melanoma transplants in the hamster cheek pouch. , 1966, Laboratory investigation; a journal of technical methods and pathology.
[37] D. Cheresh,et al. Adhesion events in angiogenesis. , 2001, Current opinion in cell biology.
[38] J. Tarbell,et al. Kinetics of placenta growth factor/vascular endothelial growth factor synergy in endothelial hydraulic conductivity and proliferation. , 2001, Microvascular research.
[39] M. Barcos,et al. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] T W Gardner,et al. Effect of vascular endothelial growth factor on cultured endothelial cell monolayer transport properties. , 2000, Microvascular research.
[41] Dwayne G Stupack,et al. ECM Remodeling Regulates Angiogenesis: Endothelial Integrins Look for New Ligands , 2002, Science's STKE.
[42] R. Jain,et al. During angiogenesis, vascular endothelial growth factor regulate natural killer cell adhesion to tumor endothelium , 1996, Nature Medicine.
[43] B. Neustadt,et al. Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. , 2000, Advances in experimental medicine and biology.
[44] Rakesh K Jain,et al. Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.
[45] D. Cheresh,et al. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.
[46] R. Jain,et al. Vascular Morphogenesis and Remodeling in a Human Tumor Xenograft: Blood Vessel Formation and Growth After Ovariectomy and Tumor Implantation , 2001, Circulation research.
[47] J. Folkman,et al. Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.
[48] R K Jain,et al. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. , 1997, The American journal of pathology.
[49] A. Boulares,et al. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. , 1998, Cancer research.
[50] R. Jain,et al. Vasculogenic mimicry: how convincing, how novel, and how significant? , 2000, The American journal of pathology.
[51] P. Burri. Intussusceptive microvascular growth, a new mechanism of capillary network formation. , 1992, EXS.
[52] Lei Xu,et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.
[53] H. Adlercreutz,et al. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. , 1997, Cancer research.
[54] J. Folkman,et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes , 2004, Angiogenesis.
[55] P. Meltzer,et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.
[56] P. Chiarugi,et al. Endostatin: A Promising Drug for Antiangiogenic Therapy , 1999, The International journal of biological markers.
[57] H. Augustin,et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.
[58] R. Jain,et al. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. , 1991, Cancer research.
[59] K. Messmer,et al. The fine structure of tumor blood vessels. I. Participation of non-endothelial cells in tumor angiogenesis. , 1985, International journal of microcirculation, clinical and experimental.
[60] R. Jain,et al. Vascular Morphogenesis and Remodeling in a Model of Tissue Repair: Blood Vessel Formation and Growth in the Ovarian Pedicle After Ovariectomy , 2001, Circulation research.
[61] H. Dvorak. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] R. Jain,et al. Effect of local anti-VEGF antibody treatment on tumor microvessel permeability. , 1999, Microvascular research.
[63] G. Winter,et al. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices , 2002, Gene Therapy.
[64] Koichi Hattori,et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.
[65] Napoleone Ferrara,et al. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.
[66] D. Paper. Natural products as angiogenesis inhibitors. , 1998, Planta medica.
[67] R K Jain,et al. Delivery of Molecular Medicine to Solid Tumors , 1996, Science.
[68] R. Brekken,et al. Vascular endothelial growth factor and vascular targeting of solid tumors. , 2001, Anticancer research.
[69] P. D’Amore,et al. Cellular interactions in vascular growth and differentiation. , 2001, International review of cytology.
[70] G. Palade,et al. Neovasculature induced by vascular endothelial growth factor is fenestrated. , 1997, Cancer research.
[71] R Pasqualini,et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. , 1998, The Journal of clinical investigation.